Survey
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
Atlas of Genetics and Cytogenetics in Oncology and Haematology OPEN ACCESS JOURNAL AT INIST-CNRS Leukaemia Section Short Communication t(2;13)(p16;q12) Jean-Loup Huret Genetics, Dept Medical Information, University of Poitiers, CHU Poitiers Hospital, F-86021 Poitiers, France Published in Atlas Database: September 2007 Online updated version: http://AtlasGeneticsOncology.org/Anomalies/t0213p16q12ID1212.html DOI: 10.4267/2042/38586 This work is licensed under a Creative Commons Attribution-Non-commercial-No Derivative Works 2.0 France Licence. © 2008 Atlas of Genetics and Cytogenetics in Oncology and Haematology pathways, such as the Ras/Raf/MAPK and PI3 kinase cascades. Clinics and pathology Disease Results of the chromosomal anomaly Myeloproliferative disorder (atypical chronic myelogenous leukaemia (a-CML)). Note: BCR-ABL negative myeloproliferative disease undistinguishable from CML otherwise. Hybrid gene Only one case to date, a 32-year-old female patient. Description Fusion of exon 3 of SPTBN1 and exon 13 of FLT3. Prognosis Fusion protein Unknown; the patient received bone marrow transplantation, relapsed 4 years later, and was in complete remission 6 months after treatment of the relapse. Description Encodes a 66 kDa protein which retains the 2 coiledcoil domains of SPTBN1 and the tyrosine kinase domain of FLT3. Expression localisation Expresssion of the fusion protein transformed Ba/F3 cells to growth factor independance. Oncogenesis Constitutive phosphorylation. Epidemiology Genes involved and Proteins SPTBN1 Protein Scaffold protein; forms homo-tetrameres; nonerythrocytic beta-spectrin; joins the actin cytoskeleton to the plasma membrane. References Grand FH, Iqbal S, Zhang L, Russell NH, Chase A, Cross NC. A constitutively active SPTBN1-FLT3 fusion in atypical chronic myeloid leukemia is sensitive to tyrosine kinase inhibitors and immunotherapy. Exp Hematol 2007 Aug 29;35(11):1723-1727. FLT3 Location: 13q12 Protein Class III receptor tyrosine kinase (RTK); promotes signalling through posphorylation of multiple proteins and activation of several downstream signalling Atlas Genet Cytogenet Oncol Haematol. 2008;12(5) This article should be referenced as such: Huret JL. t(2;13)(p16;q12). Atlas Genet Cytogenet Oncol Haematol.2008;12(5):405. 405